Isolation and seasonal variation of fruticin in fruits of false indigo-bush (Amorpha fruticosa L. Fabaceae) from Serbia

STEVAN SAMARDŽIĆ1, ALEKSANDRA TUCOVIĆ1, DANILO STOJANOVIĆ2, AND ZORAN MAKSIMOVIĆ1*

1 University of Belgrade - Faculty of Pharmacy, Department of Pharmacognosy, Vojvode Stepe 450, 11221 Belgrade, Serbia
2 University of Belgrade - Faculty of Pharmacy, Department of Botany, Vojvode Stepe 450, 11221 Belgrade, Serbia
* Corresponding author: zmaksim1@pharmacy.bg.ac.rs

Received: September 7, 2020
Accepted: November 11, 2020
Published on-line: December 22, 2020
Published: December 25, 2020

Fruticin (amorphin) is a constituent of the fruit of the false indigo-bush (Amorpha fruticosa L.), which belongs to the class of rotenoid glycosides, and shows several interesting pharmacological activities. The aim of this study was to isolate and chemically characterize this natural product, as well as to determine the optimal period of the year for A. fruticosa fruits collection. Fruticin was obtained by re-crystallization of the precipitate that formed after partial evaporation of the extract, prepared by 3-fold extraction of powdered plant material by chloroform - ethanol (1:1, v/v). The structure of the final product was determined by various techniques of instrumental analysis (NMR, UV and MS), and confirmed by comparing the obtained spectra with corresponding data in available literature. The content of fruticin in A. fruticosa fruit was determined by LC-DAD-MS, using the external standard method based on the constructed calibration curve. Limits of detection (LOD) and quantification (LOQ) were also determined. A substantial increase in fruticin content was observed during the ripening period (>50 %). It has also been established that the optimal time for fruit collection is mid-December. Obtained results indicate that the content of fruticin in the A. fruticosa fruit is highly dependable on the time of collection. Since the biosynthesis of secondary plant metabolites is influenced not only by the time of collection, but by numerous other factors as well, additional studies are needed to define, with greater certainty, the conditions that are necessary for design of prospective efficient and sustainable production process.

Key words: Amorpha fruticosa L., fruticin, isolation, chemical characterization, seasonal variation

http://dx.doi.org/10.5937/leksir2040052S

1. INTRODUCTION

Amorpha fruticosa L. (Fabaceae), also known as false indigo-bush or desert false indigo, is a shrub autochthonous to North America. It was first introduced in Europe by the beginning of the 18th century as a horticultural plant esteemed for its ornamental qualities, as well as a melliferous species. Due to its strong and well-developed root system, A. fruticosa has been planted as a protection against erosion and along the railroads to firm up the railway embankments (Krpan et al., 2011). A. fruticosa blooms in late spring till early summer. In early autumn, A. fruticosa bears fruit regularly and abundantly. Its fruits are small (up to 1 cm long) warty pods, containing one seed each. In addition to generative reproduction, it also propagates by vegetative multiplication through rootstock shoots. It is best suited to neutral, slightly acidic or alkaline, moist soils and grows near water, along the river banks, where from it spreads by water (seed pods are buoyant), especially during floods (Krpan et al., 2011).

Thanks to specific biological properties and ability to easily adapt and invade disturbed ecosystems of lowland floodplain forests, pastures, meadows or vacant soils, A. fruticosa escaped cultivation and expanded around the globe (Hulina, 2010). Today, it is recognized as one of the most invasive species for Europe, with serious deleterious effects on local autochthonous lowland flora (Krpan et al., 2011). As a heliophilic plant, it competes for the light and forms dense thickets that overshadow and suffocate the native flora, changing successional patterns and reducing biodiversity (Kozuharova et al., 2017; Krpan et al., 2011; Szigetvári, 2002). It is also widespread in Serbia, especially in Vojvodina, Mačva, and wider Belgrade area (Lazarević et al., 2012; Radulović et al., 2008). Bearing in mind the damage that this plant causes not only to floristic diversity and forestry, but also to water management, drainage systems, roads etc., its presence should be reduced, or con-
trolled by any cost. So far, the methods of biological (Gagić et al., 2008), chemical (Blagojević et al., 2015) and mechanical (Szigiétvári, 2002) control of the distribution of this plant have been proposed, but with certain limitations. For that reason, some alternative approaches to the problem of A. fruticosa control have recently emerged, with focus on the possibilities of the employment of this plant, rather than its eradication (Ciuvăț et al., 2016; Kozuharova et al., 2017). A. fruticosa has a great bio-pharmaceutical relevance, since it is recognized as a rich source of bioactive compounds with a high diversity of pharmacological activities. Its constituents are secondary metabolites of different chemical nature, such as stilbenoids (amorfrutins), flavonoids and their derivatives, including the subgroups of flavanones, isoflavones, rotenoids, as well as terpenoids (Kozuharova et al., 2017; López Díaz, 2016; Muharini, 2016). These constituents exhibit different activities and mechanisms of action, including PPARα/γ agonist effect, cytotoxicity, inhibition of TNF-α and NF-xB, antimicrobial (antiviral, antibacterial and antifungal) activity, etc. Wide spectrum of pharmacological activities make this plant stand out due to its potential application in the treatment of different pathologies, such as diabetes mellitus, some types of cancer, as well as various infections (Kozuharova et al., 2017; López Díaz, 2016; Muharini, 2016).

In other terms, if recognized as an inexpensive source of pharmacologically active compounds for pharmaceutical and related industries, this harmful weed could be eventually brought under the sustainable control. In this context, the aim of this paper is to present the results of investigations on isolation and chemical characterization of fruticin (amorphin), a rotenoid glycoside known as the most abundant constituent of A. fruticosa fruits, in an attempt to better understand its pharmacological values.

2. MATERIALS AND METHODS

2.1. Plant material

The plant material (fruits, in different stages of maturity) was collected in the Autumn 2019, from a meadow at Kumodraž (southern suburbs of Belgrade). Sample 1 (500 g) was collected in September 2019 and used for the extraction of fruticin. Samples 2-7 (approximately 100 g per sample) were collected in 14-days intervals starting from the beginning of September 2019 and used for the quantification of fruticin. Each sample has been dried at the room temperature, for 7 days. Identification of the plant was performed in the Department of Botany, Faculty of Pharmacy, Belgrade where a voucher specimen was deposited (No. 4206HFF).

2.2. Isolation of fruticin

Ground and sifted pods of A. fruticosa (100.2 g) were extracted as described by Khodzhaev et al. (1982) by 3-fold digestion with the mixture of chloroform-ethanol (1:1, v/v) for 5.5 h, 4 h and 2.5 h. Combined extracts were reduced by vacuum evaporation to approximately 1/10 of the starting volume and solvent being removed by suction each time) and the product was re-crystallized, first with the mixture of chloroform-ethanol (1:1, v/v) for 5.5 h, 4 h and 2.5 h. Combined extracts were reduced by vacuum evaporation to approximately 1/10 of the starting volume and was well dried in vacuo. Finally, it was re-crystallized, first with the mixture of chloroform-ethanol (1:1, v/v) for 5.5 h, 4 h and 2.5 h. Combined extracts were reduced by vacuum evaporation to approximately 1/10 of the starting volume and was well dried in vacuo. Finally, it was re-crystallized, first

2.3. Chemical characterization

NMR spectra (1H, 400 MHz; 13C, 101 MHz) were recorded on Bruker AscendTM 400 instrument. Prior to analysis, the sample of fruticin was dissolved in deuterated dimethyl sulfoxide (DMSO-d6). Chemical shifts (δ) were expressed as ppm, and coupling constant (J) in Hz. As internal standard, tetramethylsilane was used (δ = 0 ppm). UV and mass spectra of fruticin were obtained using Agilent 1260 Infinity liquid chromatograph, equipped with a diode array and a single quadrupole mass detectors, after a chromatographic separation as described in the section 2.4.3.

4. LC-DAD-MS analysis

4.1. Construction of calibration curve and determination of the limits of detection and quantification

A quantity of 5.1 mg of fruticin was accurately weighed and dissolved in LC-MS grade methanol with the aid of ultrasonication. The resulting solution was transferred to a volumetric flask (5 mL) and made up to the marking. The prepared stock solution (1.02 mg/mL) was used to make a series of dilutions whose concentrations ranged between 10.2 and 680 µg/mL. The limit of detection (LOD) and limit of quantification (LOQ) were determined. LOD is the lowest concentration of analyte in a sample that can be detected, while LOQ could be defined as the lowest concentration of analyte in a sample that can be determined with acceptable precision and accuracy. LOD and LOQ were determined by calculating the standard response deviation (Sd) and the slope of the calibration curve (a) using following expressions (Malenović and Stojanović, 2010):

$$\text{LOD} = 3.3 \times \frac{Sd}{a}$$

$$\text{LOQ} = 10 \times \frac{Sd}{a}$$

4.2. Preparation of extracts

The extracts for fruticin assay were prepared essentially as described by Genkina et al. (1971). In brief, approximately 1 g of powdered herbal substance was weighed accurately, macerated 24 h with methanol (25 mL) and further shaken for 4 h at the room temperature. Prior to LC-DAD-MS analysis, the extract was filtered and quantitatively transferred into a volumetric flask. Each extract was prepared in triplicate.

4.2.3. Fruticin assay

Chromatographic separation was performed on reverse-phase analytical column Zorbax SB-Aq (3.0×150 mm, stationary phase particle size 3.5 µm), at 25 °C and mobile phase flow rate of 0.35 mL/min (injection volume: 3 µL; phase A - 0.1 % solution of formic acid in water; phase B - acetonitrile). The mobile phase gradient was programmed as follows: 25 % B (0 min), 90 % B (30 min), 90 % B (36 min), 25 % B (38 min), 25 % B (40 min). The chromatograms were recorded at 296 nm. Mass spectra were recorded at a mass range of 100 - 1000 m/z. Electrospray ionization was performed in negative mode under atmospheric pressure (N2 flow 10 L/min, nebulizer pressure 40 psi, N2 temperature 350 °C, capillary voltage 3500 V; the molecular ion was obtained at a fragmentation voltage of 100 V). Identification of fruticin in analyzed extracts was performed by comparison of retention times (Rt) and UV spectra of present constituents with Rt and UV spectrum of previously isolated fruticin, which were obtained under the same chromatographic conditions (Claissé et al., 1964). Fruticin was quantified by the external standard method at 296 nm.

3. RESULTS AND DISCUSSION

The structure of fruticin was determined on the basis of good fit of the obtained 1H and 13C NMR, UV and MS spectral data with data from the literature and calculated molecular weight (Crombie et al., 1975; Li et al., 1993; Liang et al., 2015; Sariaslani and Rosazza, 1983; Wu et al., 2015). The yield of the isolated compound was 0.14 g.
3.1. Spectral data

$^1$H NMR (400 MHz, DMSO-$d_6$): $\delta$ 7.71 (1H, d, $J = 7.2$ Hz, H-5), 6.68 – 6.54 (2H, m, H-4, H-7), 6.51 (1H, s, H-10), 5.47 (1H, t, $J = 7.9$ Hz, H-2), 5.32 (1H, s, H-11), 5.21 (1H, s, H-1), 5.13 (1H, m, H-12a), 4.52 (2H, m, H-12), 4.32 (1H, d, $J = 13.2$ Hz, H-3”), 4.27 – 4.06 (4H, m, H-12, H-3’, H-1””, H-1’”), 3.98 – 3.85 (2H, m, H-6a, H-6”), 3.77 – 3.45 (9H, m, -OCH$_3$, -OCH$_3$, H-6”, H-4””, H-5””), 3.19 – 2.90 (4H, m, H-1, H-2”, H-3”, H-4”).

$^{13}$C NMR (101 MHz, DMSO-$d_6$): $\delta$ 189.25 (C-6), 166.74 (C-3a), 158.22 (C-13a), 149.84 (C-9), 148.06 (C-10a), 144.38 (C-2’), 143.67 (C-8), 129.67 (C-5), 113.73 (C-5a), 113.30 (C-13b), 113.03 (C-1’), 111.26 (C-7), 105.57 (C-6b), 104.91 (C-4), 103.94 (C-1”), 102.74 (C-1”), 101.92 (C-10), 85.03 (C-2’), 76.99 (C-3”), 76.20 (C-5”), 73.83 (C-2’), 73.02 (C-3”), 72.20 (C-12a), 71.01 (C-2”), 70.59 (C-4”), 68.51 (C-6”), 68.22 (C-3’), 67.79 (C-4”), 66.19 (C-12), 65.36 (C-5”), 56.63 (-OCH$_3$), 56.03 (-OCH$_3$), 44.03 (C-6a), 31.27 (C-1).

UV: $\lambda_{max}$ = 200 nm, $\lambda_{max1}$ = 236 nm and $\lambda_{max2}$ = 296 nm.

ESI-MS m/z (negative mode, fragmentor voltage 100 V): 703.2 [M-H]$^-$, 749.1 [M+HCOOH-H]$^-$.

3.2. Fruticin content

The basic attributes of the calibration curve are given in Table 1. The content of fruticin (%) in the plant material is shown in Table 2.

![Fig. 1. Fruticin (amorphigenin α-L-arabinopyranosyl-1→6-O-β-D-glucopyranoside)](image)

Based on this constituent, the drug Fruticin® (50 mg) was developed in the USSR and used in 1960s and 1970s as a sedative for neurotic conditions of various origins (cardiac neurosis, vegetative-vascular dystonia, paroxysmal neurogenic tachycardia). During the use of this drug, no contraindications and side effects were observed (Anonymous, 1968; 1974; Moiseev and Ustinova, 1967; Syropyatov and Dzeruzhinskaya, 2001). Eventually, due to the emergence of novel and, presumably, more effective synthetic drugs, Fruticin® was excluded from the USSR drug register in 1982 as obsolete (Anonymous, 1982). Although retracted from the drug register, pharmacological investigations on fruticin have been continued, as the results of experimental in vitro and in vivo studies indicated its significant medical potential. Fruticin showed an inhibitory effect on rat heart phosphodiesterase. Its activity was found to be greater than the inhibitory activity of potent flavonoids such as luteolin, kaempferol, quercetin (Petkov et al., 1983). Hypercoagulability in rabbits with experimentally induced atherosclerosis was inhibited by oral administration of fruticin (Azikov et al., 1984). Administered at a dose of 5 mg/kg/day, it showed a hepatoprotective effect in a model of hyperlipemic rats. In addition, it hindered the development of experimental atherosclerosis in the presence of the combination of risk factors in rabbits. It reduced the level of cholesterol and lipoproteins that have atherogenic potential after administration of an oral dose of 10 mg/kg body weight in a model of hyperlipemic rats. In addition, it hindered the development of morphological manifestations of aortic atherosclerosis (Kurmukov et al., 1986). The cytotoxic effect of fruticin was assessed in vitro on malignant breast (MCF-7) and colon (HCT-116) cancer cell lines using the MTT assay. The results showed that fruticin exhibited selective anti-proliferative activity against the MCF-7 cell line (IC$_{50}$ = 0.95 µM/mL), even better than the positive control, cisplatin (IC$_{50}$ = 7.07 µM/mL). These results indicate that fruticin could be...
an important raw material for the production of anticancer drugs (Wu et al., 2015).

We believe that the medicinal potentials of fruticin have not been exhausted and that the use of this molecule should be re-evaluated by means of contemporary tests in the light of modern knowledge in physiological sciences.

CONCLUSION

Our results suggest that A. fruticosa fruits, as potential raw material for industrial extraction of fruticin, should be collected during the dormant phase of the plant, in late autumn or in winter. The methodology of fruticin isolation shows promising potentials for scale-up and use in industrial or semi-industrial environment, with satisfactory purity of obtained product. LC-DAD-MS or HPLC-UV/DAD could be suitable as analytical techniques for quality control assurance. Further research on fruticin pharmacology is needed and already in progress.

ACKNOWLEDGMENTS

Supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia; contract No. 451-03-68/2020-14/200161.

REFERENCES

Anonymous (1982). Order of the USSR Ministry of Health of 05/28/1982 n 503 „On exclusion from the State Register of obsolete medicines”. Accessed: 14.11.2020. [in Russian].

Ažikov, M., Rasulova, S. and Kurmukov, A. (1984). Hypocogaulatrical action of amorphin in experimental atherosclerosis, Doklady Akademii nauk USSR 10: 49–50. [in Russian].

Blažegovijević, M., Konstantinović, B., Samardžić, N., Kurjakov, A. and Orlović, S. (2015). Seed bank of Amorpha fruticosa L. on some ruderal sites in Serbia, Journal of Agricultural Science and Technology B 5(2): 122–128.

Buckingham, J. (ed.) (1993). Dictionary of Natural Products, Vol. 1, Chapman & Hall/CRC Press London, New York.

Ciuvăț, A. L., Vasiile, D., Dinu, C., Apostol, E., Apostol, B. and Petrițan, A.-M. (2016). Valorisation possibilities of invasivindigobush (Amorpha fruticosa L.) in Romania, Revista de Silvicultură și Cinegetică 21(39): 96–99.

Claizzie, J., Crombie, L. and Peace, R. (1964). 1162. Structure and stereochemistry of the vicinanoside amorphin, the first rotenoid glycoside, Journal of the Chemical Society pp. 6023–6036.

Crombie, L., Kilbee, G. W. and Whiting, D. A. (1975). Carbon-13 magnetic resonance spectra of natural rotenoids and their relatives, Journal of the Chemical Society, Perkin Transactions 1 15: 1497–1499.

Gagić, R., Mihajlović, R. and Glavendekic, M. (2008). Acanthoscelides pallidipennis (Coleoptera: Bruchidae), a sperm-matophagous insect of indigobush (Amorpha fruticosa L.) and its natural enemies in Serbia, Acta Herboligica (Serbia) 17(2): 195–201. [in Serbian].

Genkina, G. L., Shakirov, T. T. and Shamsutdinov, R. I. (1971). Improved spectrophotometric method for determining amorphine in the fruits of Amorpha fruticosa, Pharmaceutical Chemistry Journal 5: 298–300.

Hulina, N. (2010). “Planta Hortifuga” in flora of the continental part of Croatia, Agriculturae Conspectus Scientificus 75(2): 57–65.

Khodzhaev, K. N., Trofimova, N. I., Shamsutdinov, M. R. I. and Shakirov, T. T. (1982). Isolation of frutisins from the seeds Amorpha fruticosa, Chemical of Natural Compounds 18(5): 585–587.

Klošte, E., Popov, A., Drensa, D. and Uzunov, P. (1985). Experimental research on the hepatoprotective activity of flavonoids isolated from Amorpha fruticosa, Eksperimentalna Medicina i Morfologija 24(2): 50–54. [in Bulgarian].

Kozuhrarov, E., Matkowsky, A., Woźniak, D., Simeonova, R., Naychov, Z., Malainer, C., Mocan, A., Nabavi, S. M. and Atanasov, A. G. (2017). Amorpha fruticosa – a noxious invasive alien plant in Europe or a medicinal plant against metabolic disease?, Frontiers in Pharmacology 8. Article 333.

Krupan, A., Tomasić, V. and Bašić Palković, P. (2011). Biopotential of indigobush (Amorpha fruticosa L.) – second year of investigation, Šumarski list 135(13): 103–112. [in Croatian].

Kurmukov, A., Aızikov, M., Rasulova, S. and Makhmudov, O. (1986). Hypolipidemic, hypcholesterolemic and anti-sclerotic action of the rotenoid glycoside amorphin, Farmakologija i Toksikologiia 49(6): 54–57. [in Russian].

Lazarević, P., Stojanović, V., Jelić, I., Perić, R., Krsteski, B., Ajić, R. and et al. (2012). A preliminary list of invasive species in Serbia, with general measures of control and reduction as a basis of future legal acts, Zaštita prirode 62(1): 5–31. [in Serbian].

Li, L., Wang, H., Chang, J., McPhail, A., McPhail, D., Terada, H., Komoshina, T. and et al. (1993). Antitumor agents, 138. Rotenoids and isoflavones as cytotoxic constituents from Amorpha fruticosa, Journal of Natural Products 56(5): 690–698.

Liang, Y., Li, X., Gu, Z., Qin, P. and Ji, M. (2015). Toxicity of amorphigenin from the seeds of Amorpha fruticosa against the larvae of Culex pipiens pallasii (Diptera: Culicidae), Molecules 20(2): 3238–3254.

López Díaz, A. (2016). Monografía de Amorpha fruticosa L.; una planta muy polifacética, Universidad Complutense de Madrid. Final Degree Project.

Malenović, A. and Stojanović, B. (2010). Handbook of pharmaceutical analysis, University of Belgrade - Faculty of Pharmacy, Belgrade.

Moiseev, S. G. and Ustínova, E. Z. (1967). Experience in the use of the new Soviet preparation amorphin (fruticin) for the prevention of attacks of paroxysmal tachycardia, Sovetskaja Meditsina 30(12): 53–56.

Muharini, R. (2016). Bioactive Secondary Metabolites from Medicinal Plants, PhD thesis, Heinrich Heine Universität Düsseldorf, Germany.

Petkov, E., Uzunov, P., Kostova, I., Somleva, T. and Ognyanov, I. (1983). Inhibition of rat heart phosphodiesterase by some rotenoids and isoflavonoids, Planta Medica 47(4): 237–239.
Radulović, S., Skočajić, D., Bјedov, I. and Dunisijević-Bojović, D. (2008). *Amorpha fruticosa* L. on wet sites in Belgrade, *Glasnik Sumarskog fakulteta* 97: 221–233. [in Serbian].

Sariaslani, F. S. and Rosazza, J. P. (1983). Microbial transformations of natural antitumor agents: Products of rotenone and dihydrorotenone transformation by *Cunninghamella blakesleiana*, *Applied and Environmental Microbiology* 45(2): 616–621.

Syropyatov, O. and Dzeruzhinskaya, N. (2001). *Phytotherapy of psychosomatic disorders*, VEAP-ICKPiP. Kiev. [in Russian].

Szigetvári, C. (2002). Initial steps in the regeneration of a floodplain meadow after a decade of dominance of an invasive transformer shrub *Amorpha fruticosa* L., *Tiscia* 33: 67–77.

Wu, X., Liao, H.-B., Li, G.-Q., Liu, Y., Cui, L., Wu, K.-F., Zhu, X.-H. and Zeng, X.-B. (2015). Cytotoxic rotenoid glycosides from the seeds of *Amorpha fruticosa*, *Fitoterapia* 100: 75–80.